Literature DB >> 20732302

Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase.

Amit V Pandey1, Christa E Flück, Primus E Mullis.   

Abstract

Human heme oxygenase-1 (HO-1) carries out heme catabolism supported by electrons supplied from the NADPH through NADPH P450 reductase (POR, CPR). Previously we have shown that mutations in human POR cause a rare form of congenital adrenal hyperplasia. In this study, we have evaluated the effects of mutations in POR on HO-1 activity. We used purified preparations of wild type and mutant human POR and in vitro reconstitution with purified HO-1 to measure heme degradation in a coupled assay using biliverdin reductase. Here we show that mutations in POR found in patients may reduce HO-1 activity, potentially influencing heme catabolism in individuals carrying mutant POR alleles. POR mutants Y181D, A457H, Y459H, V492E and R616X had total loss of HO-1 activity, while POR mutations A287P, C569Y and V608F lost 50-70% activity. The POR variants P228L, R316W and G413S, A503V and G504R identified as polymorphs had close to WT activity. Loss of HO-1 activity may result in increased oxidative neurotoxicity, anemia, growth retardation and iron deposition. Further examination of patients affected with POR deficiency will be required to assess the metabolic effects of reduced HO-1 activity in affected individuals.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20732302     DOI: 10.1016/j.bbrc.2010.08.072

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization.

Authors:  Christopher C Marohnic; Warren J Huber Iii; J Patrick Connick; James R Reed; Karen McCammon; Satya P Panda; Pavel Martásek; Wayne L Backes; Bettie Sue S Masters
Journal:  Arch Biochem Biophys       Date:  2011-06-28       Impact factor: 4.013

Review 2.  NADPH-cytochrome P450 oxidoreductase: prototypic member of the diflavin reductase family.

Authors:  Takashi Iyanagi; Chuanwu Xia; Jung-Ja P Kim
Journal:  Arch Biochem Biophys       Date:  2012-09-11       Impact factor: 4.013

3.  NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology.

Authors:  David S Riddick; Xinxin Ding; C Roland Wolf; Todd D Porter; Amit V Pandey; Qing-Yu Zhang; Jun Gu; Robert D Finn; Sebastien Ronseaux; Lesley A McLaughlin; Colin J Henderson; Ling Zou; Christa E Flück
Journal:  Drug Metab Dispos       Date:  2012-10-19       Impact factor: 3.922

4.  Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6.

Authors:  Xuan Chen; Li Qiang Pan; Hua Naranmandura; Su Zeng; Shu Qing Chen
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

Review 5.  Pharmacogenomics of human P450 oxidoreductase.

Authors:  Amit V Pandey; Patrick Sproll
Journal:  Front Pharmacol       Date:  2014-05-09       Impact factor: 5.810

Review 6.  Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine.

Authors:  Shabbir Ahmed; Zhan Zhou; Jie Zhou; Shu-Qing Chen
Journal:  Genomics Proteomics Bioinformatics       Date:  2016-10-08       Impact factor: 7.691

Review 7.  Cytochrome P450 oxidoreductase deficiency caused by R457H mutation in POR gene in Chinese: case report and literature review.

Authors:  Yang Bai; Jinhui Li; Xiaoli Wang
Journal:  J Ovarian Res       Date:  2017-03-14       Impact factor: 4.234

8.  Modeling of Anopheles minimus Mosquito NADPH-cytochrome P450 oxidoreductase (CYPOR) and mutagenesis analysis.

Authors:  Songklod Sarapusit; Panida Lertkiatmongkol; Panida Duangkaew; Pornpimol Rongnoparut
Journal:  Int J Mol Sci       Date:  2013-01-16       Impact factor: 5.923

9.  Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation.

Authors:  Ibrahim El-Serafi; Parvaneh Afsharian; Ali Moshfegh; Moustapha Hassan; Ylva Terelius
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

10.  Altered CYP19A1 and CYP3A4 Activities Due to Mutations A115V, T142A, Q153R and P284L in the Human P450 Oxidoreductase.

Authors:  Sameer S Udhane; Shaheena Parween; Norio Kagawa; Amit V Pandey
Journal:  Front Pharmacol       Date:  2017-08-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.